ReviewFrontiers in oncology2020
Genomics of Peripheral T-Cell Lymphoma and Its Implications for Personalized Medicine.
Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Primary Endometrial Lymphomas: A Systematic Review.Diagnostics (Basel, Switzerland) · 2026Review
- Born with two faces: sequential DLBCL, NOS and TFHL-AI withFrontiers in immunology · 2026Article
- A novel hybrid convolutional and transformer network for lymphoma classification.Scientific reports · 2025Article
- Phosphorylated STAT3 as a potential diagnostic and predictive biomarker in ALKFrontiers in immunology · 2023Article
- Genetic Landscape of Peripheral T-Cell Lymphoma.Life (Basel, Switzerland) · 2022Review
- Advances in the understanding and treatment of Cutaneous T-cell Lymphoma.Frontiers in oncology · 2022Review
- Molecular diagnosis of T-cell lymphoma: a correlative study of PCR-based T-cell clonality assessment and targeted NGS.Blood advances · 2021Article
- Review
- Review
- Use of cucurbitacins for lung cancer research and therapy.Cancer chemotherapy and pharmacology · 2021Review
- Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma.Experimental hematology & oncology · 2020Review
- Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.Clinical epigenetics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral T-cell lymphoma (PTCL) is a rare, heterogenous group of mature T-cell neoplasms that comprise 10-15% of non-Hodgkin lymphoma cases in the United States. All subtypes of PTCL, except for ALK
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.